About Us

More about ACT:




The ACT Team:
Artificial Cell Technologies Team
Artificial Cell Technologies, Inc. (ACT) was established in New Haven, Connecticut in 2006 to commercialize applications of its proprietary multilayer polypeptide nanofilm technology. Development of the technology began in 2001 by Dr. Donald Haynie at Louisiana Tech University where the techniques to design and construct stable, controllable, and versatile polypeptide nanofilms using the reliable layer-by-layer assembly method were perfected. This method allows for the creation of nanofilms on surfaces of virtually any shape or size, including films or coatings on flat surfaces as well as films on round template particles which create micro- or nano-particles or capsules. ACT has exclusively licensed this technology from Louisiana Tech University.

ACT's lead product candidates are vaccines for Respiratory Syncytial Virus (RSV) and malaria.  Our development programs in both RSV and malaria include collaborations with top academic as well as government partners. 

ACT is now preparing its first IND filing to begin human clinical trials of an RSV vaccine candidate which utilizes ACT's proprietary ultra-thin multilayer polypeptide nanofilms.  Advantages of ACT’s vaccine technology include:

  • Increases the immunogenicity of weakly or non-immunogenic antigens without the use of adjuvants
  • Reduces antigen dose required for immunization dramatically reducing cost of materials
  • Rapid synthetic manufacture with no egg or cell culture required, greatly reducing the chance of contamination and allowing a much faster time to market
  • Flexible design and production platform readily allows for multivalent or combination vaccines
  • Constructs are shelf stable at room temperature with a long shelf life; no cold chain storage required